Knowing early can make a difference

A new way to get earlier, more precise information after cancer treatment
What is molecular residual disease (MRD)?

MRD is the presence of small traces of cancer in the blood, such as circulating tumor DNA (ctDNA) or microscopic pieces of tumor DNA.
Why is cancer surveillance important?

Knowing early if there are traces of cancer present in your body, can help the doctor or oncologist decide:

• If you are responding to treatment
• If further cancer treatment needs to be considered
• If there are signs that the cancer has returned or progressed

The most common imaging tools used to detect the presence of cancer include computerized tomography (CT) scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan, mammography, and x-ray. These imaging tools are limited in their ability to detect molecular residual disease (MRD), which are very small traces of cancer in the blood. If left untreated, residual cancer cells are highly likely to multiply and cause a recurrence.
Signatera is a new cancer-surveillance test uniquely personalized for each patient

Signatera is a custom-designed test that is generated based on each patient’s unique set of tumor mutations.

Knowing earlier if your cancer is likely to recur or has progressed after treatment can help you have a more informed discussion with your doctor on how to continue to treat or to detect changes in your disease.

How is the Signatera test performed?

1. An analysis of both blood and tissue determines your unique set of tumor mutations
2. The test is custom-built and personalized for you
3. The test can detect the presence or absence of tumor DNA throughout the course of the cancer continuum
How long will it take to receive my test results?

**Designing your first Signatera test**
The first time the Signatera test is ordered, it will take 2 to 3 weeks from the date the tumor tissue and required blood samples are received to design your personalized test.

**After your test has been designed**
It will take ~1 week after your blood sample is received in the lab for your test results to become available to your physician.

What do my test results mean?

**If you have early-stage cancer:**

- **ctDNA**
  - Higher risk for your cancer returning
  - More likely to remain cancer-free

The Signatera test is recommended for periodic use over the course of your cancer care as directed by your doctor, to detect changes in the presence or absence of tumor DNA.

**If you have metastatic cancer:**
Your doctor may look for changes in ctDNA levels to assess your tumor’s response to treatment.
How accurate is the Signatera residual disease test?

Signatera can detect extremely small amounts of tumor DNA before cancer recurrence can be seen by traditional imaging tools such as CT scans or MRI. The Signatera test is highly sensitive and specific, meaning that if your test result is positive, there is a high likelihood that your cancer may recur without further treatment. The test’s ability to correctly identify the presence of molecular residual disease (MRD), is what makes Signatera unique.

How much does Signatera cost?

At Natera, we understand that medical tests can be expensive and billing processes can be confusing. We welcome all insurance plans and will work with you to make the test as affordable as possible. We also have an affordable self-pay rate for those patients who do not wish to use insurance. Natera expects to soon offer Medicare coverage for Stage II-III colorectal cancer (CRC).
When should the Signatera test be considered?

1. At initial cancer diagnosis, to establish a baseline before surgery or treatment
2. After surgery, before starting chemotherapy
3. During treatment, to evaluate treatment response
4. After treatment, to monitor for molecular residual disease or tumor response to treatment

Talk to your doctor for more information.

For questions or financial assistance, please contact Natera’s Patient Advocate Team.

Phone: 650.489.9050
Fax: 650.412.1962
Email: signateracc@natera.com
For more information about Signatera or to review published studies, visit
www.natera.com/signatera

Contact Natera’s Patient Advocate Team by calling 650.489.9050

Brought to you by Natera, a global leader in genetic testing and cell-free DNA analysis

About Natera, the maker of Signatera
Natera is a global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide by harnessing the power of DNA from a single blood sample to improve the management of reproductive health, cancer and organ transplants.